Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome

Summary

The goal of this clinical trial is to learn if Bifidobacterium. animalis subsp.

Lactis A6 Strain or resveratrol to improve the symptoms of diarrhea-predominate irritable bowel syndromes (IBS-D). The main questions it aims to answer are:

1. Does Bifidobacterium animalis subsp.Lactis A6 Strain or resveratrol improve the symptoms of IBS-D.
2. What is the optimal intervention dose of Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol to improve IBS-D

Researchers will compare Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol interventions to placebo (one look-alike sunbstance that contains no interventions substance) to see if Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol relief the symptoms of patients with IBS-D.

Participants will:

1. Take Bifidobacterium. animalis subsp.Lactis A6 Strain or resveratrol every day for 30 days.
2. Visit the clinic once every 15 days for checkups and tests.

Conditions

• Irritable Bowel Syndrome - Diarrhoea

Interventions

DIETARY_SUPPLEMENT

Prebiotic_L

subject will receive a low-dosage (1\*10\^5) of Bifidobacterium. animalis subsp.Lactis A6 Strain

DIETARY_SUPPLEMENT

resveratrol_L

subject will receive a low-dosage (300mg/d) of resveratrol

DIETARY_SUPPLEMENT

Prebiotic_M

subject will receive a medium-dosage (1\*10\^8) of Bifidobacterium. animalis subsp.Lactis A6 Strain

DIETARY_SUPPLEMENT

Prebiotic_H

subjects will receive a high-dosage (1\*10\^10) of Bifidobacterium. animalis subsp.Lactis A6 Strain

DIETARY_SUPPLEMENT

resveratrol_H

subject will receive a low-dosage (600mg/d) of resveratrol

OTHER

placebo_Bif

subjects will receive placebo (one look-alike sunbstance that contains no prebiotics)

OTHER

placebo_resveratrol

subjects will receive placebo (one look-alike sunbstance that contains no resveratrol)

Sponsors & Collaborators

• Peking University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-02-28

Primary Completion

2025-03-31

Completion

2025-12-31

Countries

• China

Study Locations